| MRK Stock | | | EUR 143.95 0.10 0.07% |
Director
Dr. Paul B. Rothman is Independent Director of the Company. Dr. Rothman oversees the Johns Hopkins Health System and school of medicine. A rheumatologist and molecular immunologist, he joined Johns Hopkins in July 2012 after having served as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008. He previously served as head of internal medicine at the University of Iowa from 2004 until 2008. Prior to that, he was vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1986. Dr. Rothman is a 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology and earned his medical degree from Yale University in 1984. He is a member of the American Society for Clinical Investigation and is a fellow of the American College of Physicians. He was elected to the council of Association of American Physicians as a fellow of the American Association for the Advancement of Sciences and as a member of the American Clinical and Climatological Association. since 2015.
| Age | 61 |
| Tenure | 9 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck Management Efficiency
The company has return on total asset
(ROA) of
0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
Merck Company has accumulated 7.93
B in total debt with debt to equity ratio
(D/E) of 0.65, which is about average as compared to similar companies. Merck Company has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | DIRECTOR Age |
| Art Garcia | Elanco Animal Health | 58 |
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. MERCK Kommanditgesellschaft auf Aktien operates as a subsidiary of E. MERCK KGAA operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 57850 people. Merck Company (MRK) is traded on Frankfurt Exchange in Germany and employs 63,723 people.
Management Performance
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | |
| Matthias Heinzel, CEO Board | |
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | |
| Gerhard Schmitz, Head Accounting | |
| Christine Seidman, Independent Director | |
| Kathy Warden, Independent Director | |
| Constantin Fest, Head Relations | |
| Paul Rothman, Independent Director | |
| Mary Coe, Independent Director | |
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | |
| Peter Guenter, CEO Board | |
| Barbara Weiland, Chief Officer | |
| Belen MD, Chair CEO | |
| Marcus Kuhnert, CFO Board | |
| Peter Wendell, Independent Director | |
| Friederike Rotsch, Group Compliance | |
| Leslie Brun, Lead Independent Director | |
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | |
| Inge Thulin, Independent Director | |
| Dirk Toepfer, Chief Officer | |
| Pamela Craig, Independent Director | |
| Patricia Russo, Independent Director | |
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | |
| Rita Karachun, Senior Vice President - Finance, Global Controller | |
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | |
| Kai Beckmann, CEO Board | |
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | |
| Thomas Cech, Independent Director | |
| Michael Nally, Executive Vice President, Chief Marketing Officer | |
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | |
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | |
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | |
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | |
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company
management, corporate governance, and ethical practices play a significant role. A
comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock.
Highlighted below are key reports to facilitate an investment decision about Merck Company Stock: Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.